FIG 4.

Vaccination-induced antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADCP) activity but not neutralization of the challenge strain prior to challenge. (A) Plasma IgG BAMA binding titers in response to monomeric SF162 gp120 protein or oligomeric SF162 gp140C protein after two NYVAC and five protein immunizations (week 84). (B) The plasma of B.1059 and trivalent T cell mosaic (TCM)-vaccinated macaques mediates ADCC against cells coated with SF162 gp120. The magnitude (left) and endpoint titer (right) of ADCC against SF162 gp120-coated cells are shown. Plasma from after the third (week 30), fourth (week 52), and fifth (week 84) protein boosts were assessed for activity. The box-and-whisker plots show the median, interquartile range, minimum, and maximum. The symbols represent values for individual macaques. Intrarectal challenges were initiated at week 84. (C) Antibody-mediated phagocytosis of SHIV SF162P3 gp120-coated fluorescent beads. Plasma samples prevaccination (week 0) and after the fifth (week 84) protein boost were examined for activity. Filled symbols show positive values and open symbols show negative values at week 84. (D) Week 52 plasma neutralization of tier 1 and tier 2 SHIVs, including SHIV SF162P3 used for the challenge. The neutralization titer is shown as reciprocal plasma dilution that yields 50% inhibition of virus replication (ID₅₀). Neutralization titers are color-coded based on neutralization potency as follows: white, <20; yellow, 20 to 99; orange, 100 to 999; and red >1,000. nt, not tested. (E) Plasma neutralization of the challenge virus SHIV SF162P3 on the day of challenge (week 84).